Last updated 5 days ago
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
11000 patients around the world
Available in Chile, Argentina, United States, Brazil
Alnylam Pharmaceuticals
1Research sites
11000Patients around the world
This study is for people with
Cardiovascular disease
Arterial hypertension
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Is 18 years or older for patients with established cardiovascular disease (CVD).Is 55 years or older for patients with high risk for CVD.Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD.Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic.
- Has known history of secondary hypertension.Has symptomatic orthostatic hypotension.Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×upper limit of normal (ULN).Has total serum bilirubin >1.5×ULN.Has international normalized ratio (INR) >1.5.Has serum potassium >4.8 mEq/L.Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2.
Sites
Centro Médico Saavedra
Recruiting
StudyZENITH
SponsorAlnylam Pharmaceuticals
Study typeInterventional
Conditions
Cardiovascular diseaseArterial hypertension
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07181109
